References
- Bacci G, Picci P, Ruggieri P, et al. Primary chemotherapy and delayed surgery (Neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Rizzoli experience in 127 patients treated preoperatively with methotrexate i.v. (high vs moderate dose) and cisplatinum i.a. Cancer 1990; 65: 2539–2553.
- Bacci G, Picci P, Pignatti G, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities. Clin Orthoped 1991; 270: 87–98.
- Goorin AM, Perez-Atayde A, Gebhardt M, et al. Weekly high-dose methotrexate and doxorubicin for osteosarcoma. The Dana-Farber Cancer Institute/the Children's Hospital Study III. J Clin Oncol 1987; 5: 1178–1184.
- Jaffe N, Raymond K, Ayala A, et al. Intraarterial cisdiammine -dichloroplatinum II in pediatric osteosarcoma: relationship of the effect on primary tumor to survival. In: Ryan JR, Baker O: Recent concepts in sarcoma treatment. Kluver Academic Publisher 275–282, 1988.
- Kalifa C, Mlika N, Dubosset J, et al. The experience of T10 protocol in the pediatric department of the Goustave Roussy Institute. In Ryan JR, Baker O eds. Recent concepts in sarcoma treatment. Kluver Academic Publisher 1988: 301–305.
- Rosen G, Marcove R, Caparros B, et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 1979; 43: 2163–2177.
- Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to the preoperative chemotherapy. Cancer 1982; 49: 1221–1230.
- Rosen G. Preoperative chemotherapy (neoadjuvant) chemotherapy for osteogenic sarcoma: a ten years experience. Orthopaedics 1985; 8: 659–664.
- Rosen G. The current management of malignant bone tumors: where do we go from here? Med J Australia 1988; 148: 373–377.
- Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian study. J Clin Oncol 1984; 2: 617–624.
- Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma. Results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988; 6: 329–337.
- Delepine N, Delepine G, Desbois JC. Prognostic value of drug intensity (DI) and serie intensity (SI) of MTX in osteosarcoma. Proc Am Soc Clin Oncol 1992; 11: 417.
- Saeter G, Alvegard A, Elomaa I, Stenwing AE, Holm-strom T, Solheim P. Treatment of osteosarcoma of the extremities with the T-10 protocol with emphasis on the effects of preoperative chemotherapy with single agent high dose methotrexate: a Scandinavian Sarcoma Group Study. J Clin Oncol 1987; 5: 21–28.
- Evans WE, Crom WR, Abromowitch M, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med 1986; 314: 471–477.
- Delepine N, Delepine G, Desbois JC. Implications of HDMTX pharmacokinetics for neoadjuvant chemotherapy of osteosarcoma in osteosarcoma and adult soft tissue sarcoma: present trends. S. Frustaci, A De Paoli eds. Aviano 1991: 94.
- Picci G, Bacci G, Campanacci M, et al. Histological evaluation of necrosis in osteosarcoma induced by chemotherapy. Cancer 1985; 56: 1515–1521.
- Sassoli V, Ferrari S, Strazzari S, Orlandi M, Puggioli C, Bacci G. Relazione fra necrosi tumorale e C Max, Area sotto la Curva (AUC) di Methotrexate in un trattamento polichemioterapico per l'osteosarcoma non metastatico delle estremità. Tumori 1992; 78,3 (suppl): 104.
- Goren MP, Wright RK, Horowitz ME, Meyer WH. Enhancement of methotrexate nephrotoxicity after cisplatin therapy. Cancer 1986; 58: 2617–2621.